The global “immunomodulators market” is set to gain momentum from the increasing research activities to introduce unique approaches to treat cancer effectively. This information is published by Fortune Business Insights™ in a new study, titled, “Immunomodulators Market Size, Share & Industry Analysis, By Product Type (Immunosuppressant, Immunostimulants), By Application (Oncology, Respiratory, Multiple Sclerosis, and Others), and Regional Forecast, 2020-2027.” The study further mentions that the immunomodulators market size was USD 161.57 billion in 2019. It is projected to grow from USD 186.12 billion in 2020 to USD 285.01 billion in 2027 at a CAGR of 6.3% during the forecast period.

Major Immunomodulators Market Key players covered in the report include:

  • Hoffmann-La Roche Ltd (Basel, Switzerland)
  • Novartis AG (Basel, Switzerland)
  • Biogen (Massachusetts, U.S.)
  • Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)
  • Amgen, Inc (California, U.S.)
  • Bristol-Myers & Squibb Company (New York, U.S)
  • Merck Sharp & Dohme Corp. (New jersey, U.S)
  • Eli Lilly and Company (Indiana, U.S)
  • Other Players

Get Request a Sample Copy of the Immunomodulators Report:

Our research methodology is robust and includes data triangulation based on bottom-up and top-down approaches. We validated the approximate market number with the help of primary research. Secondary research was conducted to find out detailed information about mergers and acquisitions, collaborations, joint ventures, and agreements. At the same time, we have derived significant information about the market dynamics associated with growth drivers, trends, and obstacles.

It offers figurative estimations for upcoming years on the basis of the recent developments and historic data. For gathering information and estimating revenue for all segments, researchers have used top-down and bottom-up approaches. On the basis of data collected from primary and secondary research and trusted data sources the report will help both existing and new aspirants for market to figure out and study the market’s needs, market size, and competition.

Immunomodulators Market Analysis 2021:

Drivers & Restraints-

Rising Cases of Rheumatoid Arthritis to Accelerate Growth

The higher prevalence of multiple sclerosis is considered to be the second major cause of death, followed by cardiovascular disorders. The rising number of ongoing clinical trials to develop immunotherapeutic agents, namely, laquinimod, ozanimod, and ponesimod would propel the immunomodulators market in the upcoming years. Apart from that, the rising need to treat autoimmune disorders, such as rheumatoid arthritis is anticipated to spur demand. However, immunomodulators can cause severe infections including HIB, TB, fungal infections, hepatitis B, and hepatitis C viruses. These factors may hinder the demand for such drugs.


Immunosuppressant Segment Held Highest Share Fueled by Rising Availability of Drugs

Based on the product type, the immunosuppressant segment held the majority of the immunomodulators market share in 2019. This growth is attributable to the usage of these drugs for treating autoimmune disorders, such as lupus and alopecia areata. Also, the presence of a wide range of these drugs capable of effectively treating the above-mentioned diseases would boost growth of the segment.

Investment in Quality Control to Favor Growth amid COVID-19 Pandemic

The COVID-19 pandemic is set to affect the market for immunomodulators positively in the near future backed by the increasing sales of these products. Besides, numerous pharmaceutical companies are aiming to maintain the balance between demand and supply to keep their sales intact. They are also trying to invest more in quality control, refine their R&D activities, and enhance the supply chain management. We are offering in-depth analysis of the market to help you invest in the right zones.

To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: